よむ、つかう、まなぶ。
会議資料 (167 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00046.html |
| 出典情報 | 医療上の必要性の高い未承認薬・適応外薬検討会議（第68回 5／25）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
要望番号；III➀-73
rituximab
ガイドラインの根拠
① NCCN の診療ガイドライン
論文
[72] Minard-Colin V, Aupérin A, Pillon M, et al. Rituximab for High-Risk,
Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med
2020; 382(23): 2207-2219.1)
[77] Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96
chemotherapy in children with Stage III/IV B-cell non-Hodgkin
lymphoma: a Children's Oncology Group report. Leukemia 2013; 27(5):
1174-1177.9)
[81] Goldman S, Smith L, Galardy P, et al. Rituximab with chemotherapy in
children and adolescents with central nervous system and/or bone
marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology
Group Report. Br J Haematol 2014; 167(3): 394-401.10)
[83] Frazer JK, Li KJ, Galardy PJ, et al. Excellent outcomes in children and
adolescents with CNS+ Burkitt lymphoma or other mature B-NHL using
only intrathecal and systemic chemoimmunotherapy: results from
FAB/LMB96 and COG ANHL01P1. Br J Haematol 2019; 185 (2):
374-377.11)
[122] Dourthe ME, Phulpin A, Auperin A, et al. Rituximab in addition to
LMB-based chemotherapy regimen in children and adolescents with
primary mediastinal large B-cell lymphoma: results of the French
LMB2001 prospective study. Haematologica 2022; 107(9): 2173-2182.12)
[123] Dourthe ME, Auperin A, Rigaud C, et al. Excellent outcome of
children/adolescents with primary mediastinal large B-cell lymphoma
treated with FAB/LMB-based chemotherapy regimen with rituximab.
Haematologica 2024; 109(11): 3790-3794.13)
②
米国国立がん研究所の PDQ®
[24] Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB96
chemotherapy in children with Stage III/IV B-cell non-Hodgkin
lymphoma: a Children's Oncology Groupreport. Leukemia 2013; 27(5):
1174-1177.9)
[26] Minard-Colin V, Aupérin A, Pillon M, et al. Rituximab for High-Risk,
Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med
2020; 382(23): 2207-2219.1)
[30] Barth MJ, Goldman S, Smith L, et al. Rituximab pharmacokinetics in
children and adolescents with de novo intermediate and advanced
31
167/370
rituximab
ガイドラインの根拠
① NCCN の診療ガイドライン
論文
[72] Minard-Colin V, Aupérin A, Pillon M, et al. Rituximab for High-Risk,
Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med
2020; 382(23): 2207-2219.1)
[77] Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96
chemotherapy in children with Stage III/IV B-cell non-Hodgkin
lymphoma: a Children's Oncology Group report. Leukemia 2013; 27(5):
1174-1177.9)
[81] Goldman S, Smith L, Galardy P, et al. Rituximab with chemotherapy in
children and adolescents with central nervous system and/or bone
marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology
Group Report. Br J Haematol 2014; 167(3): 394-401.10)
[83] Frazer JK, Li KJ, Galardy PJ, et al. Excellent outcomes in children and
adolescents with CNS+ Burkitt lymphoma or other mature B-NHL using
only intrathecal and systemic chemoimmunotherapy: results from
FAB/LMB96 and COG ANHL01P1. Br J Haematol 2019; 185 (2):
374-377.11)
[122] Dourthe ME, Phulpin A, Auperin A, et al. Rituximab in addition to
LMB-based chemotherapy regimen in children and adolescents with
primary mediastinal large B-cell lymphoma: results of the French
LMB2001 prospective study. Haematologica 2022; 107(9): 2173-2182.12)
[123] Dourthe ME, Auperin A, Rigaud C, et al. Excellent outcome of
children/adolescents with primary mediastinal large B-cell lymphoma
treated with FAB/LMB-based chemotherapy regimen with rituximab.
Haematologica 2024; 109(11): 3790-3794.13)
②
米国国立がん研究所の PDQ®
[24] Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB96
chemotherapy in children with Stage III/IV B-cell non-Hodgkin
lymphoma: a Children's Oncology Groupreport. Leukemia 2013; 27(5):
1174-1177.9)
[26] Minard-Colin V, Aupérin A, Pillon M, et al. Rituximab for High-Risk,
Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med
2020; 382(23): 2207-2219.1)
[30] Barth MJ, Goldman S, Smith L, et al. Rituximab pharmacokinetics in
children and adolescents with de novo intermediate and advanced
31
167/370